AstraZeneca Launches $1.5 Billion Savings Drive to Fund Drug Pipeline After Sales Beat
AstraZeneca has unveiled a restructuring programme expected to deliver about $1.5 billion in benefits to fund investment in its drug pipeline, after third-quarter results beat analyst expectations.
